Emergent BioSolutions reported $-218M in Operating Profit for its fiscal quarter ending in June of 2023.





Operating Profit Change Date
Acadia Pharmaceuticals USD 71.72M 33.88M Sep/2026
Akebia Therapeutics USD -5.45M 9.4M Dec/2025
ALKERMES USD 36.59M 102.52M Sep/2026
Alnylam Pharmaceuticals USD 179.66M 67.06M Sep/2026
Amarin USD -2.26M 564K Dec/2025
ANI Pharmaceuticals USD 51.84M 12M Sep/2026
BioMarin Pharmaceutical USD 205.6M 100M Sep/2026
Coherus Biosciences USD -39.08M 3.65M Dec/2025
Emergent BioSolutions USD -218M 69.9M Jun/2023
Exelixis USD 268.42M 20.01M Sep/2026
Glaxosmithkline GBP 2.13B 166M Sep/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Ionis Pharmaceuticals USD -130M 27.71M Sep/2026
Ironwood Pharmaceuticals USD 33.22M 7.58M Dec/2024
Lexicon Pharmaceuticals USD -14.78M 2.59M Dec/2025
Lonza CHF 673M 243M Jun/2025
Merck USD 7.33B 6.49B Sep/2026
Moderna USD 130M 945M Sep/2026
Myriad Genetics USD -3M 20.3M Dec/2025
Nektar Therapeutics USD -38.26M 19.17M Mar/2026
Neurocrine Biosciences USD 343M 123.1M Sep/2026
Pfizer USD 662M 5M Sep/2026
PTC Therapeutics USD 148.98M 103.09M Jun/2026
Sanofi EUR 4.72B 2.34B Sep/2026
Sarepta Therapeutics USD -9.04M 22.33M Sep/2026
United Therapeutics USD 241.3M 89.5M Sep/2026
Vanda Pharmaceuticals USD -40.66M 29.66M Dec/2024